Proliferative Diabetic Retinopathy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

1. INTRODUCTION

• 1.1 Study Assumptions
• 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Diabetes Increases Risk of Diabetic Retinopathy
  • 4.2.2 Availability of Advanced Technology and Minimally Invasive Laser Technique
• 4.3 Market Restraints
  • 4.3.1 Extended Approval Time for Drugs
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

• 5.1 By Treatment Type
  • 5.1.1 Anti-VEGF Agents
  • 5.1.2 Corticosteroids
  • 5.1.3 Laser Surgery
  • 5.1.4 Others
• 5.2 Geography
  • 5.2.1 North America
  • 5.2.1.1 United States
  • 5.2.1.2 Canada
  • 5.2.1.3 Mexico
  • 5.2.2 Europe
  • 5.2.2.1 Germany
  • 5.2.2.2 United Kingdom
  • 5.2.2.3 France
  • 5.2.2.4 Italy
  • 5.2.2.5 Spain
  • 5.2.2.6 Rest of Europe
  • 5.2.3 Asia-Pacific
  • 5.2.3.1 China
  • 5.2.3.2 Japan
  • 5.2.3.3 India
  • 5.2.3.4 Australia
  • 5.2.3.5 South Korea
  • 5.2.3.6 Rest of Asia-Pacific
  • 5.2.4 Middle-East and Africa
  • 5.2.4.1 GCC
  • 5.2.4.2 South Africa
  • 5.2.4.3 Rest of Middle-East and Africa
  • 5.2.5 South America
  • 5.2.5.1 Brazil
  • 5.2.5.2 Argentina
  • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Novartis AG
  • 6.1.2 Regeneron Pharmaceuticals Inc
  • 6.1.3 Allergan Plc
  • 6.1.4 Hoffmann-La Roche (Genentech)
  • 6.1.5 Oxurion NV
  • 6.1.6 Alimera Sciences
  • 6.1.7 BCN Peptides
  • 6.1.8 Glycadia Pharmaceuticals
  • 6.1.9 Kowa Group
• *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS